Literature DB >> 3787474

Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion.

C Proye, P Fossati, P Fontaine, J Lefebvre, M Decoulx, J L Wemeau, D Dewailly, E Rwamasirabo, P Cecat.   

Abstract

A pheochromocytoma that exclusively secretes dopamine (DA) rather than predominantly DA among a blend of catecholamines is as yet unreported. Of the 50 patients with pheochromocytoma who have undergone surgery, 32 underwent treatment within the last 5 years (when DA assay has been available). One half of these patients (15/32) exhibited DA secretion either in mixed catecholamines (12 patients) or exclusively (three patients). All three patients with exclusive DA-secreting tumors were normotensive. Without hypertension, the clinical investigation was a diagnostic challenge (unexplained cough or flank mass with inflammatory features). All three tumors were malignant and two were ectopic. Five of the 12 patients with mixed catecholamine-secreting tumors whose secretions included DA were hypertensive. Five other patients had flank mass and one had an unexplained cough. Tumors were rather large, and three of the tumors with mixed secretion were ectopic. Of the 12 patients, seven had tumors that were judged to be malignant. Three patients exhibited a dramatic decrease in blood pressure under alpha-blockade, which was not used in subsequent cases. Predominant or exclusive secretion of DA would explain the lack of hypertension due to its antiadrenergic action that inhibits the vasoconstrictive effects of other amines. Hypertension in patients with pheochromocytoma might depend on the ratio of DA/noradrenaline + adrenaline.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3787474

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  31 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  Paroxystic hypertension in a long-term hemodialyzed patient. Successful adrenalectomy for a dopamine-producing pheochromocytoma.

Authors:  A Ferrante; R Bellantone; A Barbarino; S Corsello; C A Rota; R Ranieri; L Sollazzi; M Sciarra; F Meo; G Luciani
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

Review 3.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

4.  Hypertension in pheochromocytoma: characteristics and treatment.

Authors:  Samuel M Zuber; Vitaly Kantorovich; Karel Pacak
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

5.  Phaeochromocytoma: a catecholamine and oxidative stress disorder.

Authors:  K Pacak
Journal:  Endocr Regul       Date:  2011-04

Review 6.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

7.  Dopamine-Secreting Paraganglioma in the Retroperitoneum.

Authors:  Yusuke Matsuda; Noriko Kimura; Takanobu Yoshimoto; Yoshihiro Sekiguchi; Junzo Tomoishi; Ichiro Kasahara; Yoshihito Hara; Yoshihiro Ogawa
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

8.  Pheochromocytoma--recent advances in diagnosis and treatment.

Authors:  N L Benowitz
Journal:  West J Med       Date:  1988-05

Review 9.  Update on pediatric pheochromocytoma.

Authors:  Bas Havekes; Johannes A Romijn; Graeme Eisenhofer; Karen Adams; Karel Pacak
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

Review 10.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.